Biosyngen Appoints Dr. Zheng Biao as Chief Executive Officer to Drive Global Expansion of Cell and Gene Therapies

On May 20, 2022, a company focusing on gene therapy and cell drug research, development, and transformation --BRL Medicine Inc. (hereinafter referred to as "BRL Medicine") announced the appointment of Dr. Zhengbiao Zheng as a senior partner of BRL Medicine Inc., serving as the Chief Executive Officer (CEO) of the company, fully responsible for the company's operation and management.Dr. Zheng Biao has over 30 years of deep involvement in the pharmaceutical industry, particularly in the field of immunotherapy, including autoimmune diseases, cancer immunology, and vaccine development. He possesses profound insights and extensive experience in drug research and development, pipeline strategy, the international pharmaceutical landscape, market access, and commercialization.

Dr. Zheng BiaoWith rich industrial experience, including in international large pharmaceutical enterprises and domestic biopharmaceutical companies. Dr. Zheng Biao joined GlaxoSmithKline (GSK) R&D Center in 2010 to lead immunology research. Since 2015, he has served as the Global Vice President of Janssen Pharmaceuticals, Johnson & Johnson, responsible for innovative drug development in the immunology field in the Asia-Pacific region, including cancer immunotherapy and autoimmune diseases. Before joining BRL Medicine, Dr. Zheng Biao served as the Chief Scientific Officer of IASO Biotherapeutics.

Dr. Zheng Biao

Dr. Zheng Biao graduated from the Department of Medicine, Zhejiang University School of Medicine, with a Bachelor's degree in Clinical Medicine; he subsequently obtained a Master’s degree in Immunology from Fudan University School of Medicine in Shanghai and a Ph.D. in Immunology from King's College, University of London. He has held teaching positions at the University of Maryland School of Medicine and Duke University Medical Center. Later, he served as a tenured professor in the Department of Pathology and Immunology at Baylor College of Medicine. Dr. Zheng Biao has an extensive list of academic publications, with several papers published in world-renowned journals such as Nature and Science.

Dr. Mingyao Liu, founder and chairman of BRL Medicine, extended a warm welcome to Dr. Zhengbiao Zheng's joining:"Dr. Zheng Biao has extensive experience in drug development, commercialization, and international cooperation, particularly in the fields of immunotherapy, cell therapy, and gene therapy. As a company committed to becoming a global leader in cell and gene therapies, BRL Medicine Inc. has long adhered to a corporate strategy driven by technology innovation and R&D. We are very pleased to have Dr. Zheng Biao join BRL Medicine Inc., and I am confident that he will play a key role in advancing the development and globalization of BRL Medicine’s innovative technology platforms. With his wealth of professional expertise and industrial experience, combined with BRL Medicine's future strategic direction and R&D priorities, Dr. Zheng Biao will lead the company in accelerating the development of cell therapies for cancer and autoimmune diseases, as well as gene therapies for genetic disorders, both in the Chinese market and globally. Together, we look forward to working hand-in-hand to witness BRL Medicine becoming a world-leading cell and gene therapy enterprise, contributing to the advancement of human health!"

Mr. Xi Zaixi, Founder and Vice Chairman of BRL Medicine, stated:"Dr. Zhengbiao Zheng is very welcome to join BRL Medicine as the Chief Executive Officer. Since officially launching the 'Global Partner Recruitment Plan' in 2020, BRL Medicine has attracted a group of senior partners with an entrepreneurial spirit and a global perspective, significantly accelerating the translation and implementation of BRL Medicine's cell and gene therapies! The strong partnership culture and entrepreneurial atmosphere, along with a competitive global development strategy and leading innovative technology platform, have drawn together like-minded entrepreneurial partners. An increasing number of top international talents are joining our ranks, participating in the thriving field of cell and gene therapy, which fills us with great excitement! Talent is the driving force behind the company’s rapid growth. Dr. Zhengbiao Zheng brings extensive industrial experience in new drug development, target research, preclinical and clinical trials, and international cooperation. We firmly believe that under the leadership of Dr. Zhengbiao Zheng, BRL Medicine will accelerate its product innovation, industrial development, and international collaboration. I am also delighted and look forward to working with Dr. Zhengbiao Zheng and all colleagues at BRL Medicine to realize our grand vision and advance gene and cell therapies for the benefit of humanity!"

Dr. Zheng Biao said:"Delighted to join BRL Medicine, and honored to step into the role of Senior Partner and Chief Executive Officer (CEO). In recent years, innovative drug development in the cell and gene therapy field has transitioned from the perception and cognition stages to market application. The implementation of scientific research technologies cannot be achieved without innovation and breakthroughs. Currently, BRL Medicine boasts world-leading R&D platforms and innovative products, and their numerous accomplishments in transforming scientific research into tangible products have left a deep impression on me. Moving forward, I hope to leverage my professional background and years of experience in the biopharmaceutical industry to collaborate with colleagues at BRL Medicine, accelerate the new drug development process, bring more high-quality products to market sooner for the benefit of patients, and work together towards making BRL Medicine a globally leading gene and cell therapy company!"

BRL Medicine Inc. is committed to becoming a globally leading cell and gene therapy company in the era of new commercial civilization. With the mission of "Leading innovation through gene editing, developing breakthrough therapies, and benefiting all humanity," BRL Medicine has generated more than 100 patent achievements over the past five years, relying on its self-developed center and the "Shanghai Gene Editing and Cell Therapy Research Center" co-built with universities. Currently, five projects are undergoing investigator-initiated clinical trials in eight renowned hospitals, with multiple projects entering the IND application stage. Notably, gene-editing treatments for β-thalassemia, PD1-knockout non-viral targeted integration CAR-T, and UCART have shown excellent clinical outcomes, demonstrating global leadership, and have been published in prestigious academic journals such as Nature Medicine and Nature Biotechnology. BRL Medicine has established five proprietary technology platforms: a gene-editing technology innovation platform, a hematopoietic stem cell platform, a non-viral targeted integration CAR-T platform, a universal cell platform, and an enhanced T-cell platform. The company also operates a 7,000-square-meter GMP pilot production base and a 200-plus-member operations team, ensuring rapid translation and application of innovative research results. By continuously driving the rapid iteration of R&D products based on patient needs and clinical feedback, BRL Medicine upholds an open, shared, and win-win attitude, working with global innovative biopharmaceutical ecosystem enterprises to accelerate the transformation and implementation of innovative drugs, benefiting patients with genetic diseases and malignant tumors worldwide!